RUPISTAR: A Study in Patients With ESR1-Mutated ER-Positive, HER2-Negative Advanced Breast Cancer
Sponsor: Evexta Bio
Phase: 3
Disease: ER-positive, HER2-negative advanced or metastatic breast cancer
EU trial number: 2026-527387-33-00
Population: Adults with ER-positive, HER2-negative advanced or metastatic breast cancer harboring an ESR1 mutation.
Register Investigator Interest
Interested in offering this trial to suitable patients?